查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840717

CBD 消費者健康市場（按產品類型和應用）—2025-2032 年全球預測

CBD Consumer Health Market by Product Type, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，CBD 消費者健康市場將成長至 415.6 億美元，複合年成長率為 16.24%。

主要市場統計數據
基準年2024年 124.6億美元
預計2025年 144.9億美元
預測年份：2032年 415.6億美元
複合年成長率（%） 16.24%

簡要介紹當前消費者 CBD 健康格局、其加速發展以及對策略決策者的影響

隨著社會對植物來源療法態度的轉變以及人們對傳統藥物替代品日益成長的需求，CBD健康類別已從最初的小眾好奇發展成為注重健康的消費者群體的主流關注對象。過去幾年，產品創新和零售擴張拓展了該類別的覆蓋範圍，包括藥房櫃檯、專業健康零售商以及以數位為先的直銷管道。同時，科學探索和臨床研究興趣正在增強目標適應症的可信度，並推動更成熟的購買體驗，將臨床功效與生活方式定位相結合。

同時，政策和法律規範持續影響標籤、分銷和行銷的可接受性，影響產品設計和企業合規模式。因此，商業領袖正在快速進行商業性試驗，並採取風險知情的聲明、測試和供應鏈透明度方法。因此，能夠展示嚴格品管、可靠證據和清晰訊息的公司將贏得消費者和通路合作夥伴的信任。

本執行摘要的其餘部分將揭示不斷變化的形勢，評估近期關稅行動的累積效應，提供細緻的細分見解，揭示區域模式和競爭行為，並為尋求將見解轉化為行動的領導者提供實用建議。

快速的產品創新、監管調整和消費者成熟度如何重塑競爭動態和長期價值創造

這些措施正在加速產品創新，拓展CBD的交付和體驗方式；監管調整限制並明確了允許的活動；臨床和品質證據標準也不斷提高，將普通產品與值得信賴的品牌區分開來。隨著監管透明度的提高，大型零售商和機構投資者對上市產品更有信心，從而鼓勵更多資本追求規模化，並進行更嚴格的研發投資以檢驗其功效。因此，該類別正從早期的實驗階段轉向以卓越營運和監管素養驅動差異化的階段。

同時，消費者也變得越來越精明。早期消費者更重視產品新穎性，而主流消費者在購買時則更重視功效、採購透明度和第三方偵測資訊。這種轉變促使品牌在臨床合作、真實世界證據收集和供應鏈可追溯性方面進行投資。零售商正透過提高驗收標準和要求更嚴格的認證來應對這項挑戰，獎勵在品質保證和文件記錄方面表現優異的公司，同時提高低品質製造商的進入門檻。

最後，分銷模式也在不斷發展。雖然數位通路仍然是關鍵的成長載體，但將精準電商與店內教育和樣品相結合的全通路策略正日益受到青睞。總而言之，這些轉型有利於那些能夠將產品創新與合規框架、證據產生和全通路上市策略同步的組織。

近期關稅對採購、製造業經濟和策略供應鏈調整的整體影響（截至 2025 年）

近期的關稅措施為該類別的供應鏈帶來了新的複雜性，促使企業重新評估籌資策略和服務成本計算。進口關稅及相關貿易措施提升了近岸外包和國內加工投資的重要性，因為企業試圖保護其毛利率免受不可預測的跨境成本衝擊的影響。為此，採購團隊正在多元化其供應商組合，並提高庫存透明度，以降低關稅突然上調的風險。因此，隨著企業在靈活性和可預測性之間做出權衡，長期合約和策略供應商夥伴關係已變得司空見慣。

這些關稅主導的壓力也加速了人們對垂直整合的興趣，一些製造商尋求擁有提取和配方資產，以確保投入材料的質量，同時避免外部價格波動。同時，依賴進口最終產品的品牌正在重新調整其通路策略，轉向更高價值的產品，並強調可追溯性和認證，以證明其高階定位的合理性。同時，面臨淨利率縮水的小品牌擴大與聯合製造商合作或簽訂許可協議，以維持市場地位，而無需完全承擔回流帶來的資本負擔。

總體而言，關稅正在推動生態系統向更強的供應鏈彈性和戰略本地化邁進，同時也促進了採購、合約結構和製造夥伴關係的創新，這將塑造超越當前政策週期的競爭地位。

細分領域的洞察揭示了產品創新、臨床重點和通路策略在消費者 CBD 健康領域創造差異化價值的領域

將產品類型細分可以揭示消費者的需求和創新途徑。膠囊和軟膠囊吸引了那些尋求離散、定量劑量並與日常補充劑兼容的消費者，而油和酊劑則繼續吸引那些優先考慮劑量控制和配方透明度的用戶。烘焙點心和糖果甜點、飲料和軟糖等偏好透過可用性和風味擴大了其吸引力，但也需要嚴格的標籤和劑量一致性以維護消費者的信任。外用藥，包括潤唇膏和軟膏、乳霜和乳液以及貼片等子類別，擴大定位於疼痛管理和個人護理領域，其中配方穩定性和遞送技術至關重要。電子煙產品分為煙彈和電子煙筆，仍然是一個利基管道，由於吸入問題，正引起越來越多的監管關注。

基於應用的細分進一步明確了臨床證據和定製配方如何解鎖高階定位。從一般焦慮管理到專注於創傷後壓力症候群 (PTSD) 的配方，焦慮和壓力應用需要謹慎的聲明語言，並且通常受益於支持療效的臨床和現實世界證據。癲癇和多發性硬化症等神經系統疾病有臨床先例支持，因此需要嚴格的採購和監管協調。疼痛管理涵蓋關節炎、肌肉疼痛和神經病變疼痛，顯示局部創新、標靶給藥以及局部是關鍵的差異化因素。個人護理和護膚，包括護髮和護膚，為主流美容管道架起了橋樑，但需要明確的安全性和皮膚病學測試。睡眠障礙應用涵蓋與失眠和睡眠呼吸中止相關的管理策略，重點突出優先考慮緩釋性和與現有睡眠藥物相互作用的配方和給藥方案。

綜合起來，這些細分模式表明，產品開發和證據生成策略應根據每個子細分市場的特定監管敏感性和臨床期望進行客製化，而商業策略應使管道選擇與用戶行為和治療意圖保持一致。

區域模式和跨境動態影響監管風險、通路成熟度和全球公司的本地適應策略

美洲市場結構複雜多元，但制度化程度日益提高。聯邦層級的監管模糊性與州和地方的健全框架並存。全國性品牌可以利用強大的零售網路和消費者熟悉度，但必須應對各州層級的複雜要求和不斷變化的標籤規範。在這種環境下，與全國性零售商合作、投資合規團隊以及根據具體州制定市場推廣策略是常見的策略應對措施。

在歐洲、中東和非洲，儘管各國對安全標準和新型食品途徑的解讀仍有差異，但法律規範正逐漸協調。歐洲多個市場消費者意識的提升，推動了對經臨床驗證的產品和醫藥級生產方法的需求。同時，不斷變化的進口和認證要求要求供應商必須掌握嚴謹的監管資訊並制定本地打入市場策略，尤其對於那些既想滿足西歐挑剔的買家，又想滿足新興市場消費者對價值提案的供應商而言。

亞太地區市場成熟度參差不齊，既有嚴格監管、限制某些大麻素產品的市場，也有較為寬鬆、正在探索醫療和健康應用的司法管轄區。在成熟的城市中心，優質化和科學檢驗正成為贏得消費者信任的關鍵；而在其他市場，價格實惠以及與現有快速消費品管道的分銷合作正在推動滲透。在全部區域，人們對植物療法的文化態度以及醫療保健體系的結構將決定CBD產品是更傾向於與主流健康和醫藥管道，還是利基專業零售商接軌。

在每個地區，全球參與者必須將集中的品質和證據標準與分散的監管和商業性執行相結合，以抓住跨境商機，同時降低法律和聲譽風險。

塑造消費者 CBD 健康生態系統中主要企業和新興企業的競爭行為和企業策略

主要企業正透過證據產生、供應鏈透明度和通路多元化等措施實現差異化。其策略重點包括：投資第三方檢測和追溯系統以檢驗產品功效；發展臨床夥伴關係關係以產生可靠的療效數據；以及拓展藥房和臨床醫生青睞的管道，以滿足更高的品質保證標準。同時，敏捷挑戰者則致力於在細分領域佔據領先地位，他們專注於特定用途和交付系統，利用直銷市場建立有意義的品牌忠誠度，並利用敏捷的產品開發週期快速回應消費者回饋。

合併、策略聯盟和許可安排是加速能力建構且不過度擴張資產負債表的常見機制。同時，忽略任何一個面向——品管、臨床檢驗或通路准入——都會增加商業性風險。此外，投資者的注意力正轉向那些能夠展現重複購買行為、分銷黏性以及可靠的規避監管審查計劃的企業，從而導致對單位經濟效益和客戶生命週期價值的嚴格控制。

整體而言，競爭優勢越來越取決於科學、合規和商業化的綜合能力，而不是純粹的分銷擴張或短期促銷活動。

高階主管和投資者可以採取切實可行的優先行動，以增強韌性、抓住成長機會、管理監管和貿易動態

首先，我們將優先投資檢驗的品質系統和透明的供應鏈，以建立監管機構和消費者的信任。這包括標準化的第三方檢測、批次可追溯性以及採購和生產實踐的公開揭露。從中期來看，這些投資將減少與大型零售客戶的摩擦，並支持我們的高階定價策略。其次，我們將根據差異化證據策略調整產品系列。我們將把臨床和現實世界證據資源分配給最有可能值得檢驗的用途，例如疼痛管理和某些神經系統疾病，同時利用消費者研究來最佳化配方，以適應更注重生活方式的細分市場，例如個人護理和睡眠支持。

第三，根據關稅和貿易波動重新評估製造地，考慮近岸外包、長期供應協議或外包製造外包方案，以維持利潤率和服務水準。第四，多元化您的通路策略，在直接面對消費者的分析優勢與藥局和臨床醫師通路的可靠性之間取得平衡。最後，將情境規劃納入您的策略評估中，以便您可以根據您的商業計劃和投資藍圖，對監管變化、關稅變化和新興臨床洞察進行壓力測試。結合這些行動，可以幫助組織將洞察轉化為明確的市場定位和營運韌性。

產生洞察所採用的實證方法，包括資料來源、三角測量策略以及用於確保穩健性和有效性的檢驗方法

調查方法結合了主要和次要研究證據流，從而建構了對該品類的全面、立體的視角。主要研究包括對供應鏈領導者、零售和藥房管道的高級品類採購員、產品開發主管以及臨床顧問的結構化訪談，以了解決策促進因素和營運限制。此外，也進行了消費行為研究，定性深入地探討了目標族群的購買動機、產品認知和未滿足的需求。次要研究則包括對監管出版物、公開臨床文獻、專利態勢和零售品類分析的系統性回顧，以揭示市場動態和監管發展。

將採購聲明與可觀察到的貿易和供應商模式進行比較，根據同行評審文獻評估臨床聲音，並透過神秘購物和電子商務產品組合審核檢驗零售定位。在公共資料匱乏或監管仍存在不確定性的情況下，明確承認其局限性，並進行敏感性檢查，以確定哪些結論最容易受到政策或貿易條件變化的影響。這種混合方法提供了切實可行的見解，同時也突顯了可以透過收集更多原始資料進一步降低不確定性的領域。

簡要概括關鍵策略要點及其對整個價值鏈的經營團隊行動和相關人員協調的影響

整體而言，消費者 CBD 健康類別正朝著更制度化、對證據的期望更高以及商業模式更加複雜的方向發展。監管動態和關稅壓力正在重塑供應鏈，並推動對近岸外包和垂直整合的投資。同時，細分洞察揭示了清晰的差異化途徑。有些產品類型和治療用途重視臨床檢驗和配方嚴謹性，而有些則受益於品牌建立和感官創新。從區域來看，持續成長需要將全球品質標準與當地監管和文化差異結合。

對於領導者而言，成功顯然需要一系列綜合能力，包括合規性、臨床證據、供應鏈韌性和通路策略。採取積極主動措施（例如強化品質系統、將證據生成用於高價值用途以及根據貿易現實調整製造佈局）的公司將佔據有利地位，能夠將監管和市場波動轉化為競爭優勢。下一步，企業應將這些洞察轉化為具體的投資和產業計畫，並優先考慮短期韌性和長期品牌完整性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 快速引入奈米乳液 CBD 配方，以提高生物有效性和功效
  • 根據個人健康指標和目標量身定做的個人化 CBD 劑量應用程式的激增
  • 將 CBD 健康產品整合到遠端醫療平台，為遠距患者照護
  • 推出一款含有適應原的 CBD機能飲料，可全面緩解壓力
  • CBD 對透明、第三方測試和區塊鏈可追溯性的需求日益成長
  • CBD補充劑微劑量通訊協定的興起以及焦慮和睡眠支持
  • CBD品牌轉型為永續包裝和碳中和供應鏈

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. CBD 消費者健康市場（依產品類型）

  • 膠囊和軟膠囊
  • 食用
    • 烘焙點心和糖果甜點
    • 喝
    • 軟糖
  • 油和酊劑
  • 外用藥物
    • 香膏和藥膏
    • 乳霜和乳液
    • 修補
  • 電子煙產品
    • 墨水匣
    • 電子煙

9. CBD 消費者健康市場（按應用）

  • 焦慮和壓力
    • 整體焦慮
    • PTSD
  • 神經系統疾病
    • 癲癇
    • 多發性硬化症
  • 疼痛管理
    • 關節炎
    • 肌肉疼痛
    • 神經病變疼痛
  • 個人護理和化妝品
    • 護髮
    • 護膚
  • 睡眠障礙
    • 失眠
    • 睡眠呼吸中止症

10. CBD消費者健康市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 11 章：CBD 消費者健康市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

12. CBD消費者健康市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第13章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Charlotte's Web Holdings, Inc.
    • Social CBD, Inc.
    • Medterra CBD LLC
    • Green Roads Health, LLC
    • Lazarus Naturals, LLC
    • cbdMD, Inc.
    • CV Sciences, Inc.
    • CBDfx LLC
    • PlusCBD Oil, Inc.
    • Endoca Holland BV
Product Code: MRR-A339DAEFA242

The CBD Consumer Health Market is projected to grow by USD 41.56 billion at a CAGR of 16.24% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 12.46 billion
Estimated Year [2025] USD 14.49 billion
Forecast Year [2032] USD 41.56 billion
CAGR (%) 16.24%

A concise orientation to the current consumer CBD health landscape, its accelerating evolution, and implications for strategic decision-makers

The consumer CBD health category has matured from niche curiosity to a mainstream consideration among health-conscious consumers, catalyzed by shifting societal attitudes toward plant-based therapeutics and a growing appetite for alternatives to traditional pharmaceuticals. Over the past several years, product innovation and retail expansion have broadened the category's footprint across pharmacy counters, specialty wellness retailers, and digital-first direct-to-consumer channels. At the same time, scientific inquiry and clinical interest have elevated credibility for targeted indications, prompting more sophisticated buyer journeys that combine clinical claims with lifestyle positioning.

Meanwhile, policy and regulatory frameworks continue to shape what is permissible in labeling, distribution, and marketing, which in turn influence product design and corporate compliance models. As a result, commercial leaders are balancing rapid commercial experimentation with risk-aware approaches to claims, testing, and supply chain transparency. Consequently, companies that can demonstrate rigorous quality controls, credible evidence, and clear messaging are better positioned to win the trust of both consumers and channel partners.

The remainder of this executive summary will unpack the transformative shifts in the landscape, assess the cumulative effects of recent tariff actions, surface nuanced segmentation insights, highlight regional patterns and competitive behaviors, and conclude with pragmatic recommendations for leaders seeking to convert insight into action.

How rapid product innovation, regulatory recalibration, and consumer sophistication are reshaping competitive dynamics and long-term value creation

The landscape has been reshaped by three interlocking forces: accelerated product innovation that expands how CBD is delivered and experienced, regulatory recalibration that constrains and clarifies permissible activity, and a rising standard of clinical and quality evidence that separates commodity offerings from trusted brands. These forces are reinforcing each other; as regulations clarify, larger retailers and institutional buyers gain confidence to list products, prompting more capital to pursue scale and more rigorous R&D investments to validate claims. Consequently, the category is moving from early-stage experimentation to a phase where operational excellence and regulatory literacy drive differentiation.

Concurrently, consumer sophistication is rising. Early adopters prioritized novelty, but mainstream buyers evaluate efficacy, sourcing transparency, and third-party testing information during purchase. This shift incentivizes brands to invest in clinical collaborations, real-world evidence collection, and supply chain traceability. Retailers are responding by tightening onboarding criteria and demanding robust certifications, which increases barriers to entry for low-quality manufacturers while rewarding firms that excel in quality assurance and documentation.

Finally, distribution models are evolving. Digital channels continue to be an important growth vector, but omnichannel strategies that combine e-commerce precision with in-store education and sampling are gaining traction. In sum, these transformative shifts favor organizations that can synchronize product innovation with compliance frameworks, evidence generation, and an omnichannel go-to-market approach.

The aggregated influence of recent tariff measures on sourcing, manufacturing economics, and strategic supply chain adjustments through 2025

Recent tariff actions have introduced a new layer of complexity into the category's supply chains, prompting companies to reassess sourcing strategies and cost-to-serve calculations. Import duties and related trade measures have elevated the importance of nearshoring and domestic processing investments as firms seek to insulate gross margins from unpredictable cross-border cost shocks. In response, procurement teams are diversifying supplier portfolios and increasing inventory visibility to reduce exposure to sudden duty increases. Consequently, long-term contracting and strategic supplier partnerships have become more common as firms trade off flexibility for predictability.

These tariff-driven pressures have also accelerated interest in vertical integration, with some manufacturers exploring ownership stakes in extraction and formulation assets to secure input quality while buffering against external price volatility. Meanwhile, brands that rely on imported finished goods are recalibrating channel strategies, shifting to higher-value offerings and emphasizing traceability and certification as a way to justify premium positioning. At the same time, smaller brands facing tightened margins are increasingly forming alliances with co-manufacturers or pursuing licensing arrangements to maintain market presence without absorbing the full capital burden of reshoring.

In total, tariffs have nudged the ecosystem toward greater supply chain resilience and strategic localization, while simultaneously driving innovation in procurement, contract structuring, and manufacturing partnerships that will shape competitive positioning beyond the immediate policy cycle.

Segment-level insights that reveal where product innovation, clinical focus, and channel strategies are creating differentiated value across the consumer CBD health universe

Examining product-type segmentation reveals distinct consumer needs and innovation pathways. Capsules and softgels attract consumers seeking discrete, measured dosing and compatibility with daily supplement routines, while oils and tinctures continue to serve users focused on dose control and formulation transparency. Edibles, including baked goods and confectionery, beverages, and gummies, have expanded accessibility and flavor-driven appeal, but they also demand rigorous labeling and dosing consistency to preserve consumer trust. Topicals, with subcategories such as balms and salves, creams and lotions, and patches, are increasingly positioned within pain management and personal care contexts where formulation stability and delivery technology matter. Vape products, divided into cartridges and vape pens, remain a niche channel with heightened regulatory attention due to inhalation concerns, which has pushed some incumbents to deprioritize this route in favor of non-inhalation delivery systems.

Application-based segmentation further clarifies where clinical evidence and tailored formulations can unlock premium positioning. Anxiety and stress applications, from general anxiety management to PTSD-focused formulations, require careful claim language and often benefit from clinical or real-world evidence to support efficacy. Neurological disorder applications, such as epilepsy and multiple sclerosis, are anchored by clinical precedent and therefore demand rigorous sourcing and regulatory alignment. Pain management spans arthritis, muscle aches and pains, and neuropathic pain, signaling that topical innovation, targeted delivery, and cross-modal strategies combining oral and topical approaches are key differentiators. Personal care and cosmetics, including hair care and skincare, offer a bridge to mainstream beauty channels but require clear safety and dermatological testing. Sleep disorder applications, covering insomnia and sleep apnea-related management strategies, spotlight formulations and delivery profiles that prioritize sustained-release and interaction with existing sleep therapeutics.

Taken together, these segmentation patterns indicate that product development and evidence-generation strategies should be tailored to the specific regulatory sensitivities and clinical expectations of each subsegment, while commercial strategies must align channel choice with user behavior and therapeutic intent.

Regional patterns and cross-border dynamics that influence regulatory risk, channel maturity, and local adaptation strategies for global players

The Americas exhibit a heterogeneous but increasingly institutionalized market structure where regulatory ambiguity at the federal level coexists with robust state and provincial frameworks. This creates both opportunity and complexity: domestic brands can leverage strong retail networks and consumer familiarity, yet they must navigate a patchwork of state-level requirements and evolving labeling norms. In such an environment, partnerships with national retailers, investment in compliance teams, and state-specific go-to-market playbooks are common strategic responses.

In Europe, the Middle East & Africa, regulatory frameworks are progressively harmonizing around safety standards and novel-food pathways, though national interpretations still vary. Consumer awareness is rising across several European markets, driving demand for clinically supported products and pharmaceutical-grade manufacturing practices. At the same time, evolving import and certification requirements necessitate careful regulatory intelligence and local market entry strategies, particularly for suppliers aiming to serve both Western European discretionary buyers and emerging market consumers seeking value propositions.

Asia-Pacific reflects a spectrum of maturity levels, from highly regulated markets that restrict certain cannabinoid products to more permissive jurisdictions experimenting with medical and wellness applications. In mature urban centers, premiumization and scientific validation are becoming central to winning consumer trust, while in other markets, affordability and distribution partnerships with established FMCG channels drive penetration. Across the region, cultural attitudes toward botanical therapies and the structure of healthcare systems will dictate whether CBD products align more closely with mainstream wellness, pharmaceutical channels, or niche specialty retailers.

Across regions, global players must blend centralized quality and evidence standards with decentralized regulatory and commercial execution to capture cross-border opportunities while mitigating legal and reputational risk.

Competitive behavior and corporate strategies shaping the leading and emerging companies in the consumer CBD health ecosystem

Leading companies are differentiating through a blend of evidence generation, supply chain transparency, and channel diversification. Strategic priorities include investing in third-party testing and traceability systems to validate product claims, forging clinical partnerships to produce credible efficacy data, and expanding into pharmacy and clinician-recommended channels that reward higher levels of quality assurance. At the same time, nimble challengers are pursuing niche leadership by focusing on specific applications or delivery systems, leveraging direct-to-consumer marketing to build meaningful brand loyalty, and using agile product development cycles to respond rapidly to consumer feedback.

Mergers, strategic alliances, and licensing arrangements are common mechanisms for accelerating capability build-out without overextending balance sheets. Companies that combine manufacturing strength with strong marketing and regulatory affairs teams tend to scale more sustainably, while those that neglect any one dimension-be it quality control, clinical validation, or channel access-face elevated commercial risk. Moreover, investor interest has shifted toward businesses that can demonstrate repeat purchase behavior, distribution stickiness, and a credible plan for navigating regulatory scrutiny, which reinforces a discipline around unit economics and customer lifetime value.

Overall, competitive advantage is increasingly a function of integrated capability across science, compliance, and commercialization, rather than purely distributional breadth or short-term promotional activity.

Practical, prioritized actions that senior executives and investors can implement to strengthen resilience, capture growth, and manage regulatory and trade dynamics

First, prioritize investment in verifiable quality systems and transparent supply chain practices to establish trust with both regulators and consumers. This includes standardized third-party testing, batch traceability, and publicly accessible documentation of sourcing and manufacturing practices. In the medium term, such investments reduce friction with large retail customers and support premium pricing strategies. Second, align product portfolios with differentiated evidence strategies: allocate clinical and real-world evidence resources to the applications most likely to reward validation, such as pain management and certain neurological indications, while using consumer research to optimize formulations for more lifestyle-oriented segments like personal care and sleep support.

Third, re-evaluate manufacturing footprint in light of tariff and trade volatility by exploring nearshoring, long-term supply agreements, or contracted manufacturing options that preserve margin and service levels. Fourth, diversify channel strategies to balance direct-to-consumer analytics with the credibility benefits of pharmacy and clinician channels; tailored merchandising, training, and clinician education programs frequently unlock high-value partnerships. Finally, embed scenario planning into strategic reviews so that regulatory shifts, tariff changes, or new clinical findings can be stress-tested against commercial plans and investment roadmaps. Taken together, these actions will help organizations convert insight into defensible market positions and operational resilience.

Empirical approach deployed to generate insights, including data sources, triangulation strategies, and validation methods used to ensure robustness and relevance

The research methodology combined primary and secondary evidence streams to create a robust, triangulated view of the category. Primary research included structured interviews with supply chain leaders, senior category buyers across retail and pharmacy channels, product development executives, and clinical advisors to capture decision drivers and operational constraints. In parallel, consumer behavior studies provided qualitative depth on purchase motivations, product perceptions, and unmet needs among target cohorts. Secondary research comprised a systematic review of regulatory publications, public clinical literature, patent landscapes, and retail assortment analyses to contextualize market dynamics and regulatory trajectories.

To ensure validity, findings from different sources were cross-checked and reconciled: procurement claims were compared with observable trade and supplier patterns, clinical assertions were evaluated against peer-reviewed literature, and retail positioning was validated through mystery shopping and e-commerce assortment audits. Limitations were explicitly acknowledged where public data is sparse or regulatory opacity persists, and sensitivity checks were performed to identify which conclusions were most susceptible to changing policy or trade conditions. This mixed-methods approach delivers actionable insights while transparently flagging areas where additional primary data collection would further reduce uncertainty.

A concise synthesis of the key strategic takeaways and their implications for executive action and stakeholder alignment across the value chain

In synthesis, the consumer CBD health category is evolving toward greater institutionalization, higher evidence expectations, and more sophisticated commercial models. Regulatory dynamics and tariff pressures are restructuring supply chains and prompting investments in nearshoring and vertical integration. At the same time, segmentation insights reveal clear vectors for differentiation: certain product types and therapeutic applications reward clinical validation and formulation rigor, while others benefit from branding and sensory innovation. Regionally, companies must align global quality standards with local regulatory and cultural nuances to unlock durable growth.

For leaders, the implication is clear: success will require integrated capabilities across compliance, clinical evidence, supply chain resilience, and channel strategy. Those who act proactively-strengthening quality systems, targeting evidence generation to high-value applications, and adapting manufacturing footprint to trade realities-will be better positioned to convert regulatory and market disruptions into competitive advantage. As a next step, organizations should translate these insights into concrete investment and operating plans that prioritize both short-term resilience and long-term brand credibility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of nanoemulsion CBD formulations enhancing bioavailability and efficacy
  • 5.2. Surge in personalized CBD dosing apps tailored to individual health metrics and goals
  • 5.3. Integration of CBD wellness products into telehealth platforms for remote patient care
  • 5.4. Emergence of CBD functional beverages infused with adaptogens for holistic stress relief
  • 5.5. Growing demand for transparent third-party testing and blockchain traceability in CBD
  • 5.6. Rise of microdosing protocols for targeted anxiety and sleep support in CBD supplements
  • 5.7. Shift toward sustainable packaging and carbon-neutral supply chains in CBD brands

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CBD Consumer Health Market, by Product Type

  • 8.1. Capsules & Softgels
  • 8.2. Edibles
    • 8.2.1. Baked Goods & Confectionery
    • 8.2.2. Beverages
    • 8.2.3. Gummies
  • 8.3. Oils & Tinctures
  • 8.4. Topicals
    • 8.4.1. Balms & Salves
    • 8.4.2. Creams & Lotions
    • 8.4.3. Patches
  • 8.5. Vape Products
    • 8.5.1. Cartridges
    • 8.5.2. Vape Pens

9. CBD Consumer Health Market, by Application

  • 9.1. Anxiety & Stress
    • 9.1.1. General Anxiety
    • 9.1.2. PTSD
  • 9.2. Neurological Disorders
    • 9.2.1. Epilepsy
    • 9.2.2. Multiple Sclerosis
  • 9.3. Pain Management
    • 9.3.1. Arthritis
    • 9.3.2. Muscle Aches & Pains
    • 9.3.3. Neuropathic Pain
  • 9.4. Personal Care & Cosmetics
    • 9.4.1. Hair Care
    • 9.4.2. Skincare
  • 9.5. Sleep Disorders
    • 9.5.1. Insomnia
    • 9.5.2. Sleep Apnea

10. CBD Consumer Health Market, by Region

  • 10.1. Americas
    • 10.1.1. North America
    • 10.1.2. Latin America
  • 10.2. Europe, Middle East & Africa
    • 10.2.1. Europe
    • 10.2.2. Middle East
    • 10.2.3. Africa
  • 10.3. Asia-Pacific

11. CBD Consumer Health Market, by Group

  • 11.1. ASEAN
  • 11.2. GCC
  • 11.3. European Union
  • 11.4. BRICS
  • 11.5. G7
  • 11.6. NATO

12. CBD Consumer Health Market, by Country

  • 12.1. United States
  • 12.2. Canada
  • 12.3. Mexico
  • 12.4. Brazil
  • 12.5. United Kingdom
  • 12.6. Germany
  • 12.7. France
  • 12.8. Russia
  • 12.9. Italy
  • 12.10. Spain
  • 12.11. China
  • 12.12. India
  • 12.13. Japan
  • 12.14. Australia
  • 12.15. South Korea

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Analysis
    • 13.3.1. Charlotte's Web Holdings, Inc.
    • 13.3.2. Social CBD, Inc.
    • 13.3.3. Medterra CBD LLC
    • 13.3.4. Green Roads Health, LLC
    • 13.3.5. Lazarus Naturals, LLC
    • 13.3.6. cbdMD, Inc.
    • 13.3.7. CV Sciences, Inc.
    • 13.3.8. CBDfx LLC
    • 13.3.9. PlusCBD Oil, Inc.
    • 13.3.10. Endoca Holland B.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASEAN CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GCC CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPEAN UNION CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. BRICS CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. G7 CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. NATO CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. CBD CONSUMER HEALTH MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. CBD CONSUMER HEALTH MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CBD CONSUMER HEALTH MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GENERAL ANXIETY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GENERAL ANXIETY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GENERAL ANXIETY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GENERAL ANXIETY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GENERAL ANXIETY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GENERAL ANXIETY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PTSD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PTSD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PTSD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PTSD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PTSD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PTSD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MUSCLE ACHES & PAINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MUSCLE ACHES & PAINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MUSCLE ACHES & PAINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MUSCLE ACHES & PAINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MUSCLE ACHES & PAINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MUSCLE ACHES & PAINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY HAIR CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY HAIR CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY HAIR CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY HAIR CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY HAIR CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY HAIR CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SKINCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SKINCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SKINCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SKINCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SKINCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SKINCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INSOMNIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INSOMNIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INSOMNIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INSOMNIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INSOMNIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INSOMNIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP APNEA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP APNEA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP APNEA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP APNEA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP APNEA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP APNEA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST CBD CONSUM